Fideuram Intesa Sanpaolo Private Banking S.P.A. Sells 13,229 Shares of Cencora, Inc. $COR

Fideuram Intesa Sanpaolo Private Banking S.P.A. lowered its holdings in shares of Cencora, Inc. (NYSE:COR) by 54.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,236 shares of the company’s stock after selling 13,229 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A.’s holdings in Cencora were worth $3,530,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blue Capital Inc. acquired a new stake in shares of Cencora during the 1st quarter valued at about $240,000. Keybank National Association OH lifted its position in shares of Cencora by 21.7% during the 1st quarter. Keybank National Association OH now owns 17,702 shares of the company’s stock worth $5,561,000 after buying an additional 3,159 shares during the period. Twin City Private Wealth LLC boosted its stake in Cencora by 3.8% in the 1st quarter. Twin City Private Wealth LLC now owns 2,549 shares of the company’s stock valued at $801,000 after buying an additional 93 shares in the last quarter. Essex Financial Services Inc. boosted its stake in shares of Cencora by 4.2% in the 1st quarter. Essex Financial Services Inc. now owns 1,310 shares of the company’s stock valued at $411,000 after purchasing an additional 53 shares in the last quarter. Finally, Fulton Bank N.A. boosted its stake in shares of Cencora by 13.2% in the 1st quarter. Fulton Bank N.A. now owns 6,160 shares of the company’s stock valued at $1,935,000 after purchasing an additional 719 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other Cencora news, Director Lauren M. Tyler bought 550 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were bought at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the transaction, the director owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.38% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on COR. Barclays cut their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating for the company in a report on Wednesday, June 10th. Evercore set a $360.00 price objective on shares of Cencora in a research note on Wednesday, April 8th. Leerink Partners restated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Citigroup dropped their price target on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Finally, Bank of America lifted their price objective on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a research report on Wednesday, June 24th. Eleven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Cencora Stock Performance

Shares of Cencora stock opened at $296.43 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The firm has a 50 day simple moving average of $277.91 and a 200 day simple moving average of $320.37. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The firm has a market cap of $57.67 billion, a P/E ratio of 22.73, a P/E/G ratio of 1.65 and a beta of 0.58.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the prior year, the company posted $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts predict that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its Board of Directors has initiated a share repurchase plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s payout ratio is currently 18.40%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.